Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 4/20 | 0.47 |
| ▸ | TUBB | P07437 | 4/20 | 0.47 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.47 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.47 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.47 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.47 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.47 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.47 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.47 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.47 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 0.47 |
| ▸ | TUBA1C | Q9BQE3 | 4/20 | 0.47 |
| ▸ | TUBB6 | Q9BUF5 | 4/20 | 0.47 |
| ▸ | TUBB2B | Q9BVA1 | 4/20 | 0.47 |
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL786713 | 0.90 | CHEK1 (0.43) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL786712 | 0.82 | NPC1 (0.50) | KDM4EMAPTRAB9ANPC1CASP3 | |
| SCHEMBL771403 | 0.81 | KMT2A (0.54) | KDM4EMAPTCDK4CCNA2CCND1 | |
| SCHEMBL28525140 | 0.80 | SYK (0.52) | KDM4EMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL11656533 | 0.79 | RAB9A (0.62) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL786708 | 0.79 | ITK (0.50) | KDM4EMAPTRAB9ANPC1CASP3 | |
| SCHEMBL12224207 | 0.78 | MEN1 (0.57) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL31612798 | 0.77 | NEK5 (0.44) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL786559 | 0.76 | HTR2B (0.44) | KDM4EMAPTRAB9ANPC1CASP3 | |
| SCHEMBL725078 | 0.76 | MAP3K11 (0.50) | MEN1KMT2AMAPK14PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023196632-A1 | METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS | VERU INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230321045-A1 | METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS | VERU INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230265081-A1 | METHODS OF TREATING CORONAVIRUS | VERU INC. (US) | 2023-08-24 | — | — | US | disclosed |
| US-11648236-B2 | Methods of treating coronavirus | VERU INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Oncternal Therapeutics, Inc. (US) | 2022-01-27 | — | — | US | disclosed |
| US-20210308105-A1 | METHODS OF TREATING CORONAVIRUS | VERU INC. (US) | 2021-10-07 | — | — | US | disclosed |
| US-11084811-B2 | Compounds for treatment of cancer | Oncternal Therapeutics, Inc. (US) | 2021-08-10 | — | — | US | disclosed |
| US-20170226086-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTx. Inc. (US) | 2017-08-10 | — | — | US | disclosed |
| US-9447049-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2016-09-20 | — | — | US | disclosed |
| EP-3064204-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTx, Inc. (US) | 2016-09-07 | — | — | EP | disclosed |
| US-9334242-B2 | Compounds for treatment of cancer | GTX, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-9334242-B2 | Compounds for treatment of cancer | GTX, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-8822513-B2 | Compounds for treatment of cancer | GTX, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| WO-2012027481-A9 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2013-10-10 | — | — | WO | disclosed |
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2012-03-22 | — | — | US | disclosed |
| WO-2012027481-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2011-10-20 | — | — | US | disclosed |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2011-10-20 | — | — | US | disclosed |
| WO-2011109059-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | TUBB4A 296/4885TUBB 213/4885TUBA3C 1166/4885 |
| US-20230321045-A1 | METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS | TUBB3, TUBB1, TUBB | TUBB4A 7/4885TUBB 3/4885TUBA3C 12/4885 |
| US-11084811-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | TUBB4A 296/4885TUBB 213/4885TUBA3C 1166/4885 |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | TUBB4A 296/4885TUBB 213/4885TUBA3C 1166/4885 |
| US-20230265081-A1 | METHODS OF TREATING CORONAVIRUS | TUBB3, TUBB1, TUBB | TUBB4A 7/4885TUBB 3/4885TUBA3C 4/4885 |
| US-20170226086-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | TUBB4A 296/4885TUBB 213/4885TUBA3C 1166/4885 |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | TUBB4A 296/4885TUBB 213/4885TUBA3C 1166/4885 |
| US-11648236-B2 | Methods of treating coronavirus | TUBB3, TUBB1, TUBB | TUBB4A 7/4885TUBB 3/4885TUBA3C 4/4885 |
| US-20210308105-A1 | METHODS OF TREATING CORONAVIRUS | TUBB3, TUBB1, TUBB | TUBB4A 7/4885TUBB 3/4885TUBA3C 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.